Insider Trading

Notable insider buying and selling activity across public companies.

Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.

Articles

11,898 total articles

Natera Director Rowan Chapman Executes $642,535 Stock Sale Amid Board Expansion and Analyst Initiations

Natera Director Rowan Chapman Executes $642,535 Stock Sale Amid Board Expansion and Analyst Initiations

Natera, Inc. (NASDAQ: NTRA) director Rowan E. Chapman completed a transaction disposing of 2,964 shares of common stock on June 16, 2026, resulting in proceeds totaling $642,535. The shares were sold at a recorded price of $216.78 each. This transaction was executed in accordance with a Rule 10b5-1 trading plan established by Chapman on December 12…

Framework Ventures Offloads Shares Amid Stablecoin Development Corp Warrant Exercise and Restatement

Framework Ventures Offloads Shares Amid Stablecoin Development Corp Warrant Exercise and Restatement

Framework Ventures, holding a 10% stake in Stablecoin Development Corp (NASDAQ:SDEV), executed a sale of $26,944 in common stock on June 15, 2026. This transaction was part of a broader mechanism tied to the exercise of pre-funded warrants. Concurrently, Stablecoin Development Corp announced a restatement of its 2025 financials due to an accounting…

Stablecoin Development CEO Michael Kazley Executes Cashless Warrant Exercise, Sells $26,944 in Shares

Stablecoin Development CEO Michael Kazley Executes Cashless Warrant Exercise, Sells $26,944 in Shares

Michael Kazley, the Chief Executive Officer and Director of Stablecoin Development Corp (NASDAQ:SDEV), along with affiliated entities including R01 Fund LP, R01 Capital LLC, and R01 Capital Manager LLC, has reported significant insider transactions involving the sale of common stock and the exercise of pre-funded warrants. The activity, disclosed i…

Adaptive Biotechnologies Executive Harlan Robins Executes $1.8 Million Stock Sale Under Pre-Approved Plan

Adaptive Biotechnologies Executive Harlan Robins Executes $1.8 Million Stock Sale Under Pre-Approved Plan

Harlan S. Robins, Chief Scientific Officer at Adaptive Biotechnologies Corp (NASDAQ: ADPT), recently executed two separate stock sales totaling $1,847,941 under a Rule 10b5-1 trading plan established in March 2026. The transactions occurred on June 15 and 16, 2026, with Robins selling 100,000 shares at a weighted-average price of $17.37 and an addi…